Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gene Mutations Reveal Potential new Targets for Treating a Type of Non-Hodgkin's Lymphoma

Published: Friday, January 08, 2010
Last Updated: Friday, January 08, 2010
Bookmark and Share
Findings provide insight into a mechanism that cancer cells may use to survive.

Researchers have discovered genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin's lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease.

The study conducted by researchers at the National Cancer Institute (NCI), the National Institute for Allergy and Infectious Diseases, and the National Human Genome Research Institute, components of the National Institutes of Health, and colleagues appeared Jan. 7, 2010, in Nature.

Diffuse large B-cell lymphoma (DLBCL) originates in B cells, which are antibody-producing immune cells and one of the body's key defense mechanisms. DLBCL is the most common form of non-Hodgkin's lymphoma and represents about 30 percent of newly diagnosed cases. There are different subtypes of DLBCL that vary biologically and differ significantly in their rates of patient survival following chemotherapy. The activated B cell-like (ABC) subtype is the least responsive to currently available therapies.

When a normal B cell encounters a foreign substance, proteins on the cell surface known as B cell receptors (BCR) activate signaling pathways that tell the cell to survive and proliferate. A signaling pathway is a stepwise series of biochemical events that help regulate important cellular functions, such as proliferation and survival. Each pathway contains points at which normal signaling can become altered, causing cells to function abnormally. Alterations in signaling pathways have been found in many types of cancer cells. Previous research had suggested that BCR signaling might contribute to the development of lymphomas; however, direct genetic and functional evidence was lacking.

In the new study, researchers first used advanced laboratory techniques to identify critical points in the BCR signaling pathway that affect the survival of lymphoma cells. They found that interference with several individual components of this pathway caused lymphoma cells to die. Thus, ongoing BCR signaling - which the authors refer to as chronic active signaling - is necessary for ABC subtype DLBCL cell survival.

The team then looked for mutations in genes that encode these signaling pathway components in human DLBCL tumors. They found that about one-fifth of ABC subtype tumors had mutations in a BCR signaling component known as CD79B. The mutations increased BCR signaling by blocking a braking process that normally turns off the pathway in response to inhibitory signals.

"Our data provide important evidence that BCR signaling plays a crucial role in ABC DLBCL," said study senior author Louis M. Staudt. M.D., Ph.D., of NCI's Center for Cancer Research. "As such, this study opens up a wealth of therapeutic opportunities for this type of lymphoma and may eventually lead to clinical trials testing agents that target components of the BCR signaling pathway."

Indeed, the Staudt team found that dasatinib, a drug that is approved for the treatment of chronic myelogenous leukemia, could turn off BCR signaling by inhibiting the activity of one of the pathway's components, a protein called BTK, thereby killing ABC subtype DLBCL cells that exhibit chronic active BCR signaling.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Near-Atomic Resolution of Protein Structure Holds Promise for Drug Discovery
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy to view the architecture of a metabolic enzyme bound to a drug that blocks its activity.
Friday, May 08, 2015
National Cancer Institute Awards Two Lung Cancer CTC Development Contracts to Cynvenio Biosystems, Inc.
Company also announces additional equity investment of $2.0 million.
Tuesday, February 07, 2012
2011 Biospecimen Research Network (BRN) Symposium
The National Cancer Institute's (NCI) Biospecimen Research Network Symposium, "Advancing Cancer Research Through Biospecimen Science," will be held March 28-29, 2011, at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
Friday, January 07, 2011
NCI Announces Plans to Reinvigorate Clinical Trials
The National Cancer Institute (NCI) has announced major changes to be made in the long-established Clinical Trials Cooperative Group Program that conducts many of the nationwide trials of new cancer therapies.
Friday, December 24, 2010
National Cancer Institute Awards Nearly $4M to University of new Mexico Cancer Center
The awards support cancer nanotechnology partnership with Sandia Labs.
Wednesday, November 10, 2010
Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of a Form of Breast Cancer
The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.
Friday, May 21, 2010
Expression of Proteins Linked to Poor Outcome in Women with Ovarian Cancer
The study led by NCI scientists may provide targets for the development of novel therapies for ovarian cancer.
Wednesday, April 21, 2010
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection
Scientists have found that cancer patients produce antibodies that target abnormal glycoproteins made by their tumors.
Thursday, February 04, 2010
The Cancer Genome Atlas Identifies Distinct Subtypes of Deadly Brain Cancer
According to study the most common form of malignant brain cancer in adults appears to be four distinct molecular subtypes.
Thursday, January 21, 2010
Diet May Protect Against Gene Changes in Smokers
A new study finds that leafy green vegetables, folate, and multivitamins could serve as protective factors against lung cancer in smokers.
Thursday, January 14, 2010
Gene Mutations Reveal Potential new Targets for Treating a Type of Non-Hodgkin's Lymphoma
Findings provide insight into a mechanism that cancer cells may use to survive.
Tuesday, January 12, 2010
Drug for Multiple Myeloma Demonstrated to Extend Disease-Free Survival
Patients receiving lenalidomide following a blood stem cell transplant had their cancer kept in check longer than placebo receiving patients.
Thursday, December 24, 2009
Gene's Position in the Nucleus Can be Used to Distinguish Cancerous from Normal Breast Tissue
Researchers have identified several genes whose spatial position inside the cell nucleus is altered in invasive breast cancer.
Wednesday, December 09, 2009
Centralized Review Process Markedly Expedites Approval of Cancer Clinical Trials
CIRB for cancer clinical trials, which was created by the National Cancer Institute, expedites the time from concept to completion of crucial investigational research.
Thursday, November 05, 2009
Duplicated Gene May Explain Rare Cancer in Some Families
NCI researchers have now identified a genetic change that may lead to chordoma, a type of bone cancer, in four of the families.
Monday, October 26, 2009
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!